{"id":"W2366481835","doi":"10.1111/bjh.14125","title":"A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis","year":2016,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"Takeda Oncology","keywords":"Ixazomib; Medicine; Multiple myeloma; Renal function; Pharmacokinetics; Urology; End stage renal disease; Adverse effect; Internal medicine; Gastroenterology; Pharmacology; Proteasome inhibitor; Hemodialysis; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008428082,0.0007241809,0.001368485,0.0002237112,0.0002798201,0.0005425052,0.0002747308,0.0005244786,0.002061812],"category_scores_gemma":[0.0006259161,0.0004696483,0.000953604,0.0002522028,0.0004589901,0.0003845857,0.0001943126,0.001606362,0.0004255449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006024982,"about_ca_system_score_gemma":0.001018757,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006093052,"about_ca_topic_score_gemma":0.00166886,"domain_scores_codex":[0.9997053,0.0001169104,0.00001248715,0.00006847898,0.00004913098,0.00004765986],"domain_scores_gemma":[0.9996501,0.00004360339,0.0001018074,0.00002778449,0.00002665691,0.0001499848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5834216,0.05696893,0.04069797,0.00135027,0.003670059,0.0005162525,0.0005663097,0.003392863,0.1637565,0.0003251672,0.003822317,0.1415117],"study_design_scores_gemma":[0.1914211,0.693637,0.09713276,0.00004750055,0.001092641,0.0007377619,0.00009716913,0.002268647,0.007059826,0.0002019793,0.006255294,0.0000483619],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955274,0.001676599,0.0005538484,0.0001657157,0.00003291233,0.0009093349,0.0004188763,0.00003786672,0.0006775243],"genre_scores_gemma":[0.9933586,0.001296708,0.001394282,0.0004295194,0.00005923608,0.0008264869,0.000872221,0.0000157054,0.001747277],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002061812,"threshold_uncertainty_score":0.006897449,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01956175581877296,"score_gpt":0.3082482007602953,"score_spread":0.2886864449415223,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}